Market overview
The global alzheimer's blood test market is worth USD 299 mn in 2026 and is forecast to reach USD 2.6 bn by 2036, growing at a 24.0% CAGR. United States is the largest country market and Phosphorylated tau 217 is the largest by biomarker segment.
| Scope | Blood-based tests for Alzheimer's disease that measure phosphorylated tau and amyloid markers, used for diagnosis, patient selection for therapy and clinical trial screening. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 230 mn |
| Value 2026 | USD 299 mn |
| Value 2036 | USD 2.6 bn |
| CAGR 2026-2036 | 24.0% |
| Volume 2026 | 1,990 thousand tests |
| Volume 2036 | 20,930 thousand tests |
| Average price 2026 | USD 150 per test |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Alzheimer's Blood Test market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 299 mn |
| 2027 | USD 371 mn |
| 2028 | USD 460 mn |
| 2029 | USD 570 mn |
| 2030 | USD 707 mn |
| 2031 | USD 877 mn |
| 2032 | USD 1.1 bn |
| 2033 | USD 1.3 bn |
| 2034 | USD 1.7 bn |
| 2035 | USD 2.1 bn |
| 2036 | USD 2.6 bn |
Alzheimer's Blood Test market segmentation
By biomarker
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Phosphorylated tau 217 | 48.0% | 54.3% | USD 144 mn | 25.5% |
| Amyloid ratio tests | 30.0% | 20.8% | USD 90 mn | 19.6% |
| Multi-marker panels | 22.0% | 24.9% | USD 66 mn | 25.5% |
By setting
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Specialist memory clinics | 46.0% | 37.4% | USD 138 mn | 21.5% |
| Primary care | 24.0% | 43.0% | USD 72 mn | 31.4% |
| Clinical trials and research | 18.0% | 8.1% | USD 54 mn | 14.5% |
| Pharma and diagnostic labs | 12.0% | 11.5% | USD 36 mn | 23.5% |
By technology
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Immunoassay | 46.0% | 43.0% | USD 138 mn | 23.2% |
| Mass spectrometry | 34.0% | 34.0% | USD 102 mn | 24.0% |
| Single-molecule array and digital | 20.0% | 23.0% | USD 60 mn | 25.8% |
By test purpose
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Diagnosis | 40.0% | 38.0% | USD 120 mn | 23.4% |
| Therapy eligibility | 26.0% | 29.0% | USD 78 mn | 25.4% |
| Trial screening | 22.0% | 21.0% | USD 66 mn | 23.4% |
| Disease monitoring | 12.0% | 12.0% | USD 36 mn | 24.0% |
By test provider
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospital laboratories | 42.0% | 41.0% | USD 126 mn | 23.7% |
| Reference laboratories | 40.0% | 38.0% | USD 120 mn | 23.4% |
| Direct-to-consumer services | 18.0% | 21.0% | USD 54 mn | 25.9% |
Top 25 countries for alzheimer's blood test by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 96.0% of 2026 revenue and the 25 countries below together hold 99.2%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 161 mn | 54.0% | USD 1.3 bn | 22.9% |
| 2 | Germany | USD 24 mn | 8.0% | USD 221 mn | 24.9% |
| 3 | United Kingdom | USD 18 mn | 6.0% | USD 167 mn | 25.0% |
| 4 | Japan | USD 18 mn | 6.0% | USD 154 mn | 24.0% |
| 5 | China | USD 15 mn | 5.0% | USD 206 mn | 30.0% |
| 6 | France | USD 13 mn | 4.5% | USD 123 mn | 24.8% |
| 7 | Italy | USD 10 mn | 3.5% | USD 90 mn | 24.0% |
| 8 | Sweden | USD 10 mn | 3.5% | USD 98 mn | 25.0% |
| 9 | Netherlands | USD 9.0 mn | 3.0% | USD 77 mn | 24.0% |
| 10 | Canada | USD 7.5 mn | 2.5% | USD 64 mn | 24.0% |
| 11 | Spain | USD 1.0 mn | 0.3% | USD 8.2 mn | 23.2% |
| 12 | Australia | USD 1.0 mn | 0.3% | USD 8.2 mn | 23.2% |
| 13 | South Korea | USD 0.93 mn | 0.3% | USD 8.5 mn | 24.8% |
| 14 | Switzerland | USD 0.84 mn | 0.3% | USD 6.7 mn | 23.1% |
| 15 | Belgium | USD 0.75 mn | 0.2% | USD 6.2 mn | 23.5% |
| 16 | Denmark | USD 0.66 mn | 0.2% | USD 5.4 mn | 23.4% |
| 17 | Norway | USD 0.66 mn | 0.2% | USD 5.4 mn | 23.4% |
| 18 | Finland | USD 0.54 mn | 0.2% | USD 4.6 mn | 24.0% |
| 19 | Austria | USD 0.54 mn | 0.2% | USD 4.6 mn | 24.0% |
| 20 | Israel | USD 0.45 mn | 0.1% | USD 4.1 mn | 24.8% |
| 21 | Brazil | USD 0.45 mn | 0.1% | USD 4.6 mn | 26.3% |
| 22 | Ireland | USD 0.45 mn | 0.1% | USD 3.9 mn | 24.0% |
| 23 | Taiwan | USD 0.45 mn | 0.1% | USD 4.1 mn | 24.8% |
| 24 | Singapore | USD 0.36 mn | 0.1% | USD 3.3 mn | 25.0% |
| 25 | Poland | USD 0.36 mn | 0.1% | USD 3.3 mn | 25.0% |
| Rest of world | USD 2.5 mn | 0.8% | USD 16 mn | 20.7% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Roche
- Fujirebio
- C2N Diagnostics
- Quanterix
- Quest Diagnostics
Group 2: Regional and specialist players
- Beckman Coulter
- Siemens Healthineers
- Labcorp
- Sysmex
- Alamar Biosciences
- ADx NeuroSciences
- Araclon Biotech
- Mayo Clinic Laboratories
- Eurofins
Group 3: Emerging and niche players
- ALZpath
- Spear Bio
- Amprion
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the alzheimer's blood test market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 24.0% is calculated from the resulting values.
The market is divided by biomarker, by setting, by technology, by test purpose, by test provider. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the alzheimer's blood test market?
The global alzheimer's blood test market is estimated at USD 230 mn in 2025 and USD 299 mn in 2026.
How fast will the alzheimer's blood test market grow?
It is forecast to reach USD 2.6 bn by 2036, a compound annual growth rate of 24.0% from 2026, an increase of USD 2.3 bn.
Which country is the largest market for alzheimer's blood test?
United States is the largest market by revenue at USD 161 mn in 2026, 54.0% of the global total. The three largest countries together hold 68.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 30.0% a year from 2026 to 2036.
Which alzheimer's blood test segment is largest?
In the by biomarker split, Phosphorylated tau 217 is the largest segment with 48.0% of 2026 revenue.
Who are the leading alzheimer's blood test companies?
Global leaders include Roche, Fujirebio, C2N Diagnostics, Quanterix.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Birch Allergy TreatmentUSD 307 mn · 6.0% CAGR
- Bladder Cancer ArrayUSD 308 mn · 9.0% CAGR
- Digital StethoscopeUSD 286 mn · 10.0% CAGR
- Ophthalmic Stereoscopic 3D DisplayUSD 314 mn · 11.0% CAGR
- Dental Implantology SoftwareUSD 283 mn · 8.5% CAGR
- Bone Morphogenetic ProteinUSD 316 mn · 5.0% CAGR
- Kidney Transplant Rejection BiomarkerUSD 319 mn · 9.0% CAGR
- Veterinary Allergy DiagnosticsUSD 321 mn · 6.5% CAGR
← Advanced Implantable Electrode Neurotechnology Ambulatory Surgery Center →